STAT

Sanofi says Dupixent could be a $10 billion drug, aims to sell Cialis and Tamiflu over the counter

Sanofi says it wants to sell Cialis, the erectile dysfunction treatment, and Tamiflu, the flu drug, as over-the-counter medicines.
Technicians work on a production line at a Sanofi Genzyme site in Lyon, France.

The new CEO of Sanofi, the French drug giant, believes that its drug Dupixent, for the treatment of severe rashes and asthma, could surpass $10 billion in annual sales.

, who became CEO in September, said Monday that growing sales of Dupixent, which is sold with the U.S. biotech Regeneron, would be Sanofi’s top priority. It “has the chance to be one of the most successful medicines in the history of the industry, built on the back of patients with huge unmet need who are

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT1 min read
STAT+: In Large Trial, Guardant Health’s Blood Test Detects Colon Cancer, But Less Reliably At Earliest Or Precancerous Stages
If approved, Guardant Health’s liquid biopsy is likely to be a strong new addition to colorectal cancer screening tools, particularly for patients who currently choose not to get screened.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.

Related Books & Audiobooks